To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

NCT01193140 | Completed Phase 2

• 1 other identifier: M12-273
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 2

Brief Summary

To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.

Conditions

Solid Tumor Cancers

Keywords

veliparib; relapsed and refractory tumors; Temodar; temozolomide; ABT-888; Solid Tumors

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety and tolerability of veliparib/TMZ combination in subjects with solid tumors

  Safety and tolerability will be assessed through clinical laboratory tests, electrocardiograms (ECGs), vital signs, physical exams and adverse event assessments

  Continuous starting with Day1 and 30 Days following last dose.

Secondary Outcomes (1)

• To assess effect of veliparib/TMZ combination regimen on progression free survival, overall survival, the objective response rate, time to progression and Eastern Cooperative Oncology Group (ECOG) performance status in subjects with solid tumors

  Every 12 weeks from Day1 and continuing up to 18 months following last dose.

Study Arms (1)

Arm A

EXPERIMENTAL

Drug: veliparib; Drug: Temozolomide

Interventions

veliparib DRUG

Dose orally twice daily for 7 days, consecutively, every cycle

Also known as: ABT-888

Arm A

Temozolomide DRUG

Dose orally once daily for 5 days, consecutively, every cycle

Also known as: Temodar

Arm A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject has completed study participation in Study M11-846
• Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.
• Subject must have adequate hematologic, renal and hepatic function per institutional normal range as follows: • Bone Marrow: Absolute neutrophil count (ANC ≥ 1,500/mm3 (1.5 × 109/L); Platelets ≥ 100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.5 g/dL (1.4 mmol/L); • Renal function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) range OR creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal; • Hepatic function: AST and ALT ≤ 2.5 × the ULN range. For subjects with liver metastases, AST and ALT \< 5 × the ULN range; Bilirubin ≤ 1.5 × the ULN range. • Partial Thromboplastin Time (PTT) must be ≤ 1.5 × the ULN range and INR \< 1.5. Subjects on anticoagulant therapy (such as Coumadin) will have an appropriate PTT and INR as determined by the Investigator.
• Women of childbearing potential must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and for 90 days following completion of therapy. Women of childbearing potential must have a negative serum pregnancy test within 28 days prior to initiation of treatment and a negative urine pregnancy test on Cycle 1 Day 1 and/or post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. • Total abstinence from sexual intercourse (minimum one complete menstrual cycle); • Vasectomized partner; • Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration; • Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream); • IUD (Intrauterine Device).

You may not qualify if:

• Subject has received anticancer agent(s) or an investigational agent (except for veliparib) within 28 days prior to study drug administration. Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded.
• Subject has undergone major surgery within the previous 28 days prior to study drug administration.
• Subject has received radiotherapy within 28 days prior to study drug administration.
• Clinically significant and uncontrolled major medical condition(s) including but not limited to: • Active uncontrolled infection; • Symptomatic congestive heart failure;• Unstable angina pectoris or cardiac arrhythmia; • Psychiatric illness/social situation that would limit compliance with study requirements; • Any medical condition, which in the opinion of the Study Investigator, places the subject at an unacceptably high risk for toxicities.
• Subject is pregnant or lactating.

Sponsors & Collaborators

• Abbott: lead

Study Sites (2)

Site Reference ID/Investigator# 43022

Encinitas, California, 92024, United States

Location

Site Reference ID/Investigator# 42662

Santa Monica, California, 90404, United States

Location

MeSH Terms

Conditions

Recurrence; Neoplasms

Interventions

veliparib; Temozolomide

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Dacarbazine; Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Bhardwaj Dessai, MD

  Abbott

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2010
• First Posted: September 1, 2010
• Study Start: July 1, 2010
• Primary Completion: November 1, 2011
• Study Completion: November 1, 2011
• Last Updated: November 21, 2012

Record last verified: 2012-11

Locations

US (2)